查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1570841

抗風濕藥物市場：依產品類型、給藥途徑、藥物類別、疾病類型 - 全球預測 2025-2030

Anti-Rheumatics Market by Product Type (Biologics, Non-Biologics), Route Of Administration (Injectable, Oral, Topical), Drug Class, Disease Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗風濕藥物市值為606.7億美元，預計2024年將達632.8億美元，複合年成長率為5.12%，到2030年將達到860.9億美元。

抗風濕藥物市場包括旨在治療類風濕性關節炎和其他導致慢性發炎和關節疼痛的相關自體免疫疾病的藥物和治療方法。由於世界老化和疾病流行，對有效治療的持續需求，這個市場變得極為重要。抗風濕藥物對於緩解症狀、改善患者的生活品質和減緩疾病進展至關重要。最終使用者主要是醫院、診所和專科中心。市場成長的推動因素包括自體免疫疾病意識的提高、生技藥品和生物學名藥的進步以及新興地區醫療保健服務的擴大。此外，個人化醫療和標靶治療代表著巨大的商機，新型生技藥品和口服 JAK 抑制劑因具有改變治療模式的潛力而備受關注。

主要市場統計
基準年[2023] 606.7億美元
預測年份 [2024] 632.8億美元
預測年份 [2030] 860.9億美元
複合年成長率（%） 5.12%

然而，挑戰依然存在，包括嚴格的監管要求、高昂的藥物開發成本以及給定價策略帶來壓力的學名藥的出現。由於成本相關的限制，市場也面臨患者獲得新治療方法的機會有限。製藥公司與研究機構在研發和行銷方面的策略聯盟和合作可以改善產品供應和市場滲透。此外，創新領域的開拓時機已經成熟，包括開發新型小分子、更加關注個人化治療的生物標記，以及使用人工智慧來縮短時間並提高功效。

儘管面臨競爭壓力，透過提高安全性和減少副作用來關注產品差異化可以增加消費者的偏好。建議的策略是保持強大的管道並進行持續的市場監測，以了解不斷變化的人口和流行病學趨勢。市場的動態性質凸顯了有效的打入市場策略的重要性，以利用未滿足的需求，以及對醫療基礎設施不斷發展和法律體制不斷完善的新興經濟體進行投資。透過解決這些多方面的因素，公司可以有效地定位自己以實現持續成長。

市場動態：揭示快速發展的抗風濕藥物市場的關鍵市場洞察

供需的動態交互作用正在改變抗風濕藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業減輕政治、地理、技術、社會和經濟領域的風險，以及消費行為及其對製造成本的影響及其對採購趨勢的影響。

波特五力：駕馭抗風濕藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗風濕藥物市場的外部影響

外部宏觀環境因素在塑造抗風濕藥物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解抗風濕藥市場競爭狀況

抗風濕藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣抗風濕藥物市場供應商績效評估

FPNV定位矩陣是評估抗風濕藥市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪抗風濕藥物市場的成功之路

抗風濕藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭格局中的挑戰，利用新的商機並取得長期成功。

該報告提供了涵蓋主要焦點細分市場的全面市場分析。

1. 市場滲透率：對當前市場環境的詳細回顧。

2. 市場開拓：辨識新興市場的成長機會，評估現有產業的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢視市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 創新的抗風濕藥物給藥系統可提高患者依從性和治療結果
      • 政府措施和有利的報銷政策推動市場成長
      • 擴大新抗風濕療法的臨床試驗與研發活動
      • 改善患者獲得衛生服務的機會並改善抗風濕藥物的採用
    • 抑制因素
      • 先進的生物治療方法在發展中地區受到限制，影響了治療的可近性和公平性。
      • 患者對規定治療方案的依從性差會導致治療結果不佳並增加疾病負擔
    • 機會
      • 老年人類風濕性關節炎盛行率的增加推動了抗風濕藥物的需求
      • 加大抗風濕新藥研發投入
      • 提高患者和醫療保健專業人員對類風濕性關節炎早期診斷和治療的認知
    • 任務
      • 需要更好的診斷工具和生物標記來改善類風濕性關節炎的早期檢測和治療結果
      • 管理與長期使用抗風濕藥物相關的併發症和副作用的問題
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章抗風濕藥市場：依產品類型

  • 介紹
  • 生技藥品
    • IL-1抑制劑
    • IL-6抑制劑
    • JAK抑制劑
    • 腫瘤壞死因子抑制劑
  • 非生技藥品
    • 皮質類固醇
    • DMARD（抗逆轉錄病毒藥物）
    • NSAIDs

第7章 抗風濕藥物市場：依給藥途徑

  • 介紹
  • 注射
  • 口服
  • 局部的

第8章抗風濕藥物市場：依藥物類別

  • 介紹
  • 緩解疾病抗風濕藥物 (DMARD)
    • 生物DMARD
      • 生物相似藥DMARD
    • 合成DMARD
      • 傳統合成 DMARD
      • 標靶合成DMARD
  • 非類固醇消炎劑(NSAID)

第9章抗風濕藥物市場：依疾病類型

  • 介紹
  • 僵直性脊椎炎
  • 骨關節炎
  • 乾癬性關節炎
  • 類風濕性關節炎

第10章 北美及南美洲抗風濕藥物市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太抗風濕藥物市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲抗風濕藥物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C0147

The Anti-Rheumatics Market was valued at USD 60.67 billion in 2023, expected to reach USD 63.28 billion in 2024, and is projected to grow at a CAGR of 5.12%, to USD 86.09 billion by 2030.

The anti-rheumatics market encompasses a range of pharmaceuticals and therapies designed to treat rheumatoid arthritis and other related autoimmune conditions, which cause chronic inflammation and joint pain. This market is vital due to the persistent demand for effective treatments caused by an aging global population and increasing disease prevalence. Anti-rheumatics are critical in mitigating symptoms, improving patient quality of life, and slowing disease progression. End-users primarily include hospitals, clinics, and specialty centers. Market growth is driven by factors such as rising awareness of autoimmune disorders, advancements in biologics and biosimilars, and expanded healthcare access in emerging regions. Additionally, personalized medicine and targeted therapies represent significant opportunities, with new biologics and oral JAK inhibitors receiving attention for their potential to revolutionize treatment paradigms.

KEY MARKET STATISTICS
Base Year [2023] USD 60.67 billion
Estimated Year [2024] USD 63.28 billion
Forecast Year [2030] USD 86.09 billion
CAGR (%) 5.12%

However, challenges persist, like stringent regulatory requirements, high drug development costs, and the emergence of generic alternatives, which put pressure on pricing strategies. The market also faces limitations in terms of patient access to newer therapies due to cost-related constraints. Strategic partnerships and collaborations for research, development, and distribution among pharmaceutical companies and research institutes can lead to improved product offerings and market penetration. Furthermore, innovation areas ripe for exploration include the development of novel small molecules, increased focus on biomarkers for personalized treatment, and leveraging AI for drug discovery processes to reduce time and improve efficacy.

Despite competitive pressures, focusing on differentiating products through improved safety profiles and reduced side effects can drive consumer preference. Maintaining robust pipelines and engaging in continuous market surveillance to identify shifting demographic and epidemiological trends are recommended strategies. The market's dynamic nature highlights the importance of effective market entry strategies to capitalize on unmet needs, alongside investing in developing economies where healthcare infrastructure is growing and legal frameworks are improving. By addressing these multifaceted factors, companies can effectively position themselves for sustained growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Rheumatics Market

The Anti-Rheumatics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Innovative drug delivery systems enhancing patient compliance and therapeutic outcomes in anti-rheumatics
    • Government initiatives and favorable reimbursement policies driving market growth
    • Expansion of clinical trials and R&D activities for novel anti-rheumatic treatments
    • Increased patient access to healthcare services improving the adoption of anti-rheumatic medications
  • Market Restraints
    • Limited availability of advanced biological therapies in underdeveloped regions affecting treatment access and equity
    • Low patient adherence to prescribed treatment regimens leading to suboptimal therapeutic outcomes and increased disease burden
  • Market Opportunities
    • Increasing prevalence of rheumatoid arthritis among geriatric population driving demand for anti-rheumatics
    • Growing investment in research and development initiatives for novel anti-rheumatic drugs
    • Rising awareness among patients and healthcare providers about early diagnosis and treatment of rheumatoid arthritis
  • Market Challenges
    • The need for better diagnostic tools and biomarkers to improve early detection and treatment outcomes in rheumatoid arthritis
    • The challenge of managing comorbidities and side effects associated with long-term use of anti-rheumatic medications

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Rheumatics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Rheumatics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Rheumatics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Rheumatics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Rheumatics Market

A detailed market share analysis in the Anti-Rheumatics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Rheumatics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Rheumatics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Rheumatics Market

A strategic analysis of the Anti-Rheumatics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Rheumatics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline plc, ILTOO Pharma, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., UCB S.A., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Anti-Rheumatics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Biologics and Non-Biologics. The Biologics is further studied across IL-1 Inhibitors, IL-6 Inhibitors, JAK Inhibitors, and TNF Inhibitors. The Non-Biologics is further studied across Corticosteroids, DMARDs, and NSAIDs.
  • Based on Route Of Administration, market is studied across Injectable, Oral, and Topical.
  • Based on Drug Class, market is studied across Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The Disease-Modifying Anti-Rheumatic Drugs (DMARDs) is further studied across Biologic DMARDs and Synthetic DMARDs. The Biologic DMARDs is further studied across Biosimilar DMARDs. The Synthetic DMARDs is further studied across Conventional Synthetic DMARDs and Targeted Synthetic DMARDs.
  • Based on Disease Type, market is studied across Ankylosing Spondylitis, Osteoarthritis, Psoriatic Arthritis, and Rheumatoid Arthritis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Innovative drug delivery systems enhancing patient compliance and therapeutic outcomes in anti-rheumatics
      • 5.1.1.2. Government initiatives and favorable reimbursement policies driving market growth
      • 5.1.1.3. Expansion of clinical trials and R&D activities for novel anti-rheumatic treatments
      • 5.1.1.4. Increased patient access to healthcare services improving the adoption of anti-rheumatic medications
    • 5.1.2. Restraints
      • 5.1.2.1. Limited availability of advanced biological therapies in underdeveloped regions affecting treatment access and equity
      • 5.1.2.2. Low patient adherence to prescribed treatment regimens leading to suboptimal therapeutic outcomes and increased disease burden
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing prevalence of rheumatoid arthritis among geriatric population driving demand for anti-rheumatics
      • 5.1.3.2. Growing investment in research and development initiatives for novel anti-rheumatic drugs
      • 5.1.3.3. Rising awareness among patients and healthcare providers about early diagnosis and treatment of rheumatoid arthritis
    • 5.1.4. Challenges
      • 5.1.4.1. The need for better diagnostic tools and biomarkers to improve early detection and treatment outcomes in rheumatoid arthritis
      • 5.1.4.2. The challenge of managing comorbidities and side effects associated with long-term use of anti-rheumatic medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Rheumatics Market, by Product Type

  • 6.1. Introduction
  • 6.2. Biologics
    • 6.2.1. IL-1 Inhibitors
    • 6.2.2. IL-6 Inhibitors
    • 6.2.3. JAK Inhibitors
    • 6.2.4. TNF Inhibitors
  • 6.3. Non-Biologics
    • 6.3.1. Corticosteroids
    • 6.3.2. DMARDs
    • 6.3.3. NSAIDs

7. Anti-Rheumatics Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral
  • 7.4. Topical

8. Anti-Rheumatics Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    • 8.2.1. Biologic DMARDs
      • 8.2.1.1. Biosimilar DMARDs
    • 8.2.2. Synthetic DMARDs
      • 8.2.2.1. Conventional Synthetic DMARDs
      • 8.2.2.2. Targeted Synthetic DMARDs
  • 8.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

9. Anti-Rheumatics Market, by Disease Type

  • 9.1. Introduction
  • 9.2. Ankylosing Spondylitis
  • 9.3. Osteoarthritis
  • 9.4. Psoriatic Arthritis
  • 9.5. Rheumatoid Arthritis

10. Americas Anti-Rheumatics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Anti-Rheumatics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Anti-Rheumatics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca plc
  • 4. Biogen Inc.
  • 5. Boehringer Ingelheim GmbH
  • 6. Bristol-Myers Squibb Company
  • 7. Eli Lilly and Company
  • 8. Galapagos NV
  • 9. Gilead Sciences, Inc.
  • 10. GlaxoSmithKline plc
  • 11. ILTOO Pharma
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Regeneron Pharmaceuticals, Inc.
  • 17. Roche Holding AG
  • 18. Sanofi S.A.
  • 19. UCB S.A.
  • 20. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. ANTI-RHEUMATICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-RHEUMATICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTI-RHEUMATICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTI-RHEUMATICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-RHEUMATICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-RHEUMATICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOSIMILAR DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL SYNTHETIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 73. CANADA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 120. CHINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 129. INDIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 283. ITALY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. POLAND ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. POLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 315. POLAND ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 319. POLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. QATAR ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. QATAR ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 324. QATAR ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 328. QATAR ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 331. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 333. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 334. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 335. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 336. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
  • TABLE 337. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 338. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
  • TABLE 339. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 340. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 341. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 342. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 343. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 344. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 345. SAUDI ARABIA ANTI-RHEUMATICS